ada , dm , clinical Recommendations. Flashcards
What are some weight-related comorbidities that people with diabetes may have?
NAFLD, HF with preserved ejection fraction, obstructive sleep apnea
What are the potential risks for people with type 2 diabetes and NAFLD?
Progression to more severe stages of liver disease, including NASH, hepatic fibrosis, and cirrhosis
What are some recommended strategies for managing type 2 diabetes in people with NASH?
Lifestyle modification with a goal of weight loss, medical and/or surgical approaches to weight loss
What are some recommended strategies for managing type 2 diabetes in people with NASH?
Lifestyle modification with a goal of weight loss, medical and/or surgical approaches to weight loss
What are some recommended strategies for managing type 2 diabetes in people with NASH?
Lifestyle modification with a goal of weight loss, medical and/or surgical approaches to weight loss
Which therapies have been shown to reduce NASH activity?
Pioglitazone therapy, GLP-1 RA therapy, metabolic surgery
What is the suggested treatment for people with type 2 diabetes at intermediate to high risk of fibrosis?
Pioglitazone and/or a GLP-1 RA with evidence of benefit
How can SGLT2i therapy benefit people with NAFLD?
Reducing elevated levels of liver enzymes and hepatic fat content
How can SGLT2i therapy benefit people with NAFLD?
Reducing elevated levels of liver enzymes and hepatic fat content
How can SGLT2i therapy benefit people with NAFLD?
Reducing elevated levels of liver enzymes and hepatic fat content
What should be assessed and managed in people with NAFLD to minimize cardiovascular risk?
Cardiovascular risk factors
How have SGLT2i drugs been shown to benefit people with obstructive sleep apnea?
Reducing incident obstructive sleep apnea
What are the consensus recommendations for people with type 2 diabetes?
Access to ongoing DSMES programs, person-centered care, optimizing medication adherence, MNT, physical activity
What are the consensus recommendations for people with type 2 diabetes?
Access to ongoing DSMES programs, person-centered care, optimizing medication adherence, MNT, physical activity
What are the consensus recommendations for people with type 2 diabetes?
Access to ongoing DSMES programs, person-centered care, optimizing medication adherence, MNT, physical activity
What is the recommended duration of physical activity for adults with type 2 diabetes?
> 150 min/week of moderate- to vigorous-intensity aerobic activity
What types of training should be supplemented with aerobic activity for adults with type 2 diabetes?
Resistance, flexibility, and/or balance training
When should metabolic surgery be considered as a treatment option for type 2 diabetes?
BMI ≥40.0 kg/m2 (BMI ≥37.5 kg/m2 in people of Asian ancestry) or a BMI of 35.0–39.9 kg/m2 (32.5–37.4 kg/m2 in people of Asian ancestry) who do not achieve durable weight loss and improvement in comorbidities
When should metabolic surgery be considered as a treatment option for type 2 diabetes?
BMI ≥40.0 kg/m2 (BMI ≥37.5 kg/m2 in people of Asian ancestry) or a BMI of 35.0–39.9 kg/m2 (32.5–37.4 kg/m2 in people of Asian ancestry) who do not achieve durable weight loss and improvement in comorbidities
When should metabolic surgery be considered as a treatment option for type 2 diabetes?
BMI ≥40.0 kg/m2 (BMI ≥37.5 kg/m2 in people of Asian ancestry) or a BMI of 35.0–39.9 kg/m2 (32.5–37.4 kg/m2 in people of Asian ancestry) who do not achieve durable weight loss and improvement in comorbidities
What medications should be used in people with established CVD to reduce MACE?
GLP-1 RA or SGLT2i with proven benefit
What medication should be initiated in people with CKD and an eGFR ≥20 ml/min per 1.73 m2 and a UACR >3.0 mg/mmol (>30 mg/g)?
SGLT2i with proven benefit
What medication should be used in people with HF to improve HF and kidney outcomes?
SGLT2i
What medication should be used in people with HF to improve HF and kidney outcomes?
SGLT2i
What medication could be used in individuals without established CVD but with multiple cardiovascular risk factors?
GLP-1 RA or SGLT2i with proven benefit
What medication could be used in individuals without established CVD but with multiple cardiovascular risk factors?
GLP-1 RA or SGLT2i with proven benefit
What medication could be used in individuals without established CVD but with multiple cardiovascular risk factors?
GLP-1 RA or SGLT2i with proven benefit
Should the decision to use a GLP-1 RA or SGLT2i be dependent on baseline HbA1c?
No, it should be independent of baseline HbA1c
Should medication selection for improving cardiovascular and kidney outcomes differ for older people?
No, it should not differ
What is the recommended approach for younger people with diabetes (<40 years)?
Consider early combination therapy
What counseling is important for women with reproductive potential?
Contraception and avoiding exposure to medications that may adversely affect a fetus
